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Abstract. We propose a population model for TB-HIV/AIDS coinfection
transmission dynamics, which considers antiretroviral therapy for HIV infection
and treatments for latent and active tuberculosis. The HIV-only and TB-only
sub-models are analyzed separately, as well as the TB-HIV/AIDS full model.
The respective basic reproduction numbers are computed, equilibria and sta-
bility are studied. Optimal control theory is applied to the TB-HIV/AIDS
model and optimal treatment strategies for co-infected individuals with HIV
and TB are derived. Numerical simulations to the optimal control problem
show that non intuitive measures can lead to the reduction of the number of
individuals with active TB and AIDS.
1. Introduction. According with the World Health Organization (WHO), the hu-
man immunodeficiency virus (HIV) and mycobacterium tuberculosis are the first
and second cause of death from a single infectious agent, respectively [48]. Ac-
quired immunodeficiency syndrome (AIDS) is a disease of the human immune sys-
tem caused by infection with HIV. HIV is transmitted primarily via unprotected
sexual intercourse, contaminated blood transfusions, hypodermic needles, and from
mother to child during pregnancy, delivery, or breastfeeding [37]. There is no cure
or vaccine to AIDS. However, antiretroviral (ART) treatment improves health, pro-
longs life, and substantially reduces the risk of HIV transmission. In both high-
income and low-income countries, the life expectancy of patients infected with HIV
who have access to ART is now measured in decades, and might approach that of
uninfected populations in patients who receive an optimum treatment (see [12] and
references cited therein). However, ART treatment still presents substantial limi-
tations: does not fully restore health; treatment is associated with side effects; the
medications are expensive; and is not curative. Following UNAIDS global report
on AIDS epidemic 2013 [45], globally, an estimated 35.3 million people were living
with HIV in 2012. An increase from previous years, as more people are receiving
ART. There were approximately 2.3 million new HIV infections globally, showing
a 33% decline in the number of new infections with respect to 2001. At the same
time, the number of AIDS deaths is also declining with around 1.6 million AIDS
deaths in 2012, down from about 2.3 million in 2005.
Mycobacterium tuberculosis is the cause of most occurrences of tuberculosis (TB)
and is usually acquired via airborne infection from someone who has active TB.
It typically affects the lungs (pulmonary TB) but can affect other sites as well
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(extrapulmonary TB). In 2012, approximately 8.6 million people fell ill with TB
and 1.3 million people died from TB. Nevertheless, TB death rate dropped 45 per
cent between 1990 and 2012, and 22 million lives were saved through use of strategies
recommended by WHO [48].
Individuals infected with HIV are more likely to develop TB disease because
of their immunodeficiency, and HIV infection is the most powerful risk factor for
progression from TB infection to disease [18]. In 2012, 1.1 million of 8.6 million
people who developed TB worldwide were HIV-positive. The number of people
dying from HIV-associated to TB has been falling since 2003. However, there were
still 320 000 deaths from HIV-associated to TB in 2012, and further efforts are
needed to reduce this burden [48]. ART is a critical intervention for reducing the risk
of TB morbidity and mortality among people living with HIV and, when combined
with TB preventive therapy, it can have a significant impact on TB prevention [48].
Collaborative TB/HIV activities (including HIV testing, ART therapy and TB
preventive measures) are crucial for the reduction of TB-HIV coinfected individuals.
WHO estimates that these collaborative activities prevented 1.3 million people from
dying, from 2005 to 2012. However, significant challenges remain: the reduction of
tuberculosis related deaths among people living with HIV has slowed in recent
years; the ART therapy is not being delivered to TB-HIV coinfected patients in the
majority of the countries with the largest number of TB/HIV patients; the pace of
treatment scale-up for TB/HIV patients has slowed; less than half of notified TB
patients were tested for HIV in 2012; and only a small fraction of TB/HIV infected
individuals received TB preventive therapy [45].
The study of the joint dynamics of TB and HIV present formidable mathematical
challenges due to the fact that the models of transmission are quite distinct [36].
Some mathematical models have been proposed for TB-HIV coinfection (see, e.g.,
[2, 3, 22, 28, 30, 36, 40]). In this paper, we propose a new population model for
TB-HIV/AIDS coinfection transmission dynamics, where TB, HIV and TB-HIV
infected individuals have access to respective disease treatment, and single HIV-
infected and TB-HIV co-infected individuals under HIV and TB/HIV treatment,
respectively, stay in a chronic stage of the HIV infection.
Optimal control is a branch of mathematics developed to find optimal ways to
control a dynamic system [10, 16, 31]. While the usefulness of optimal control
theory in epidemiology is nowadays well recognized (see, e.g., [4, 26, 27, 33, 34]),
and has been applied to TB models (see, e.g., [5, 15, 19, 21, 41, 42]) and HIV models
(see, e.g., [23, 29]), to our knowledge optimal control have never been applied to a
TB-HIV/AIDS coinfection model. In this paper, we apply optimal control theory
to our TB-HIV/AIDS model and study optimal strategies for the minimization of
the number of individuals with TB and AIDS active diseases, taking into account
the costs associated to the proposed control measures.
The paper is organized as follows. The model is formulated in Section 2. The
HIV-only and TB-only sub-models of the full TB-HIV/AIDS model are analyzed in
Section 3 and the full TB-HIV/AIDS model is analyzed in Section 4. In Section 5 we
propose an optimal control problem and apply the Pontryagin maximum principle to
derive its solution. In Section 6 numerical simulations and discussion of the results
are carried out for the optimal control problem associated to the TB-HIV/AIDS
model. We end mentioning some possible future work in Section 7.
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2. Model formulation and basic properties. The model subdivides the human
population into eleven mutually-exclusive compartments, namely susceptible indi-
viduals (S), TB-latently infected individuals, who have no symptoms of TB disease
and are not infectious (LT ), TB-infected individuals, who have active TB disease
and are infectious (IT ), TB-recovered individuals (R), HIV-infected individuals with
no clinical symptoms of AIDS (IH), HIV-infected individuals under treatment for
HIV infection (CH), HIV-infected individuals with AIDS clinical symptoms (A),
TB-latent individuals co-infected with HIV (pre-AIDS) (LTH), HIV-infected indi-
viduals (pre-AIDS) co-infected with active TB disease (ITH), TB-recovered individ-
uals with HIV-infection without AIDS symptoms (RH), HIV-infected individuals
with AIDS symptoms co-infected with active TB (AT ). The total population at
time t, denoted by N(t), is given by
N(t) = S(t) + LT (t) + IT (t) +R(t) + IH(t) + CH(t) +A(t)
+ ITH(t) + LTH(t) +RH(t) +AT (t).
The susceptible population is increased by the recruitment of individuals (assumed
susceptible) into the population, at a rate Λ. All individuals suffer from natural
death, at a constant rate µ. Susceptible individuals acquire TB infection from
individuals with active TB at a rate λT , given by
λT (t) =
β1
N(t)
(IT (t) + ITH(t) +AT (t)) , (1)
where β1 is the effective contact rate for TB infection. Similarly, susceptible indi-
viduals acquire HIV infection, following effective contact with people infected with
HIV at a rate λH , given by
λH(t) =
β2
N(t)
[IH(t) + ITH(t) + LTH(t) +RH(t) + ηC CH(t) + ηA (A(t) +AT (t))] ,
(2)
where β2 is the effective contact rate for HIV transmission. The modification pa-
rameter ηA ≥ 1 accounts for the relative infectiousness of individuals with AIDS
symptoms, in comparison to those infected with HIV with no AIDS symptoms. In-
dividuals with AIDS symptoms are more infectious than HIV-infected individuals
(pre-AIDS) because they have a higher viral load and there is a positive correlation
between viral load and infectiousness [11]. On the other hand, ηC ≤ 1 translates
the partial restoration of immune function of individuals with HIV infection that
use correctly ART [12].
Remark 1. For the basic and classical SIR model, one has the force of infection F
given by F = βI, which models the transition rate from the compartment of suscep-
tible individuals S to the compartment of infectious individuals I. However, for large
classes of communicable diseases, it is more realistic to consider a force of infection F
that does not depend on the absolute number of infectious, but on their fraction with
respect to the total populationN , that is, F = β IN . In our case, the force of infection
for the HIV is given by λH =
β2
N [IH + ITH + LTH +RH + ηC CH + ηA (A+AT )].
Only approximately 10% of people infected with mycobacterium tuberculosis de-
velop active TB disease. Therefore, approximately 90% of people infected remain
latent. Latent infected TB people are asymptomatic and do not transmit TB [43].
Individuals leave the latent-TB class LT by becoming infectious, at a rate k1, or
4 C. J. SILVA AND D. F. M. TORRES
recovered, with a treatment rate τ1. The treatment rate for active TB-infected indi-
viduals is τ2. We assume that TB-recovered individuals R acquire partial immunity
and the transmission rate for this class is given by β′1λT with β
′
1 ≤ 1. Individ-
uals with active TB disease suffer induced death at a rate dT . We assume that
individuals in the class R are susceptible to HIV infection at a rate λH . On the
other hand, TB-active infected individuals IT are susceptible to HIV infection, at a
rate δλH , where the modification parameter δ ≥ 1 accounts for higher probability
of individuals in class IT to become HIV-positive. HIV-infected individuals (with
no AIDS symptoms) progress to the AIDS class A at a rate ρ1, and to the class
of individuals with HIV infection under treatment CH at a rate φ. Individuals
in the class CH leave to the class IH at a rate ω1. HIV-infected individuals with
AIDS symptoms are treated for HIV at the rate α1 and suffer induced death at a
rate dA. Individuals in the class IH are susceptible to TB infection at a rate ψλT ,
where ψ ≥ 1 is a modification parameter traducing the fact that HIV infection is
a driver of TB epidemic [24]. HIV-infected individuals (pre-AIDS) co-infected with
TB-disease, in the active stage ITH , leave this class at a rate ρ2. A fraction p of
ITH individuals take simultaneously TB and HIV treatment and a fraction q of ITH
individuals take only TB treatment. Individuals in the class ITH progress to the
class CH at a rate pρ2 and to the class RH at a rate qp2. Individuals in the class
ITH that do not take any of the TB or HIV treatments progress to the class AT at
a rate (1 − (p + q))ρ2, and suffer TB induced death rate at a rate dT . Individuals
leave LTH class at a rate τ3. A fraction r of LTH individuals take simultaneously
TB and HIV treatment and a fraction 1 − r take only TB treatment. Individuals
in the class LTH progress to the class CH at a rate rτ3 and to the class RH at a
rate (1− r)τ3. Individuals in the class LTH are more likely to progress to active TB
disease than individuals infected only with latent TB. In our model, this progression
rate is given by k2. Similarly, HIV infection makes individuals more susceptible to
TB reinfection when compared with non HIV-positive patients. The modification
parameter associated to the TB reinfection rate, for individuals in the class RH , is
given by β′2, where β
′
2 ≥ 1. Individuals in this class progress to class A, at a rate ω2.
HIV-infected individuals (with AIDS symptoms), co-infected with TB, are treated
for HIV, at a rate α2. Individuals in the class AT suffer from AIDS-TB coinfection
induced death rate, at a rate dTA. The aforementioned assumptions result in the
system of differential equations
S˙(t) = Λ− λT (t)S(t)− λH(t)S(t)− µS(t),
L˙T (t) = λT (t)S(t) + β
′
1λT (t)R(t)− (k1 + τ1 + µ)LT (t),
I˙T (t) = k1LT (t)− (τ2 + dT + µ+ δλH(t)) IT (t),
R˙(t) = τ1LT (t) + τ2IT (t)− (β′1λT (t) + λH(t) + µ)R(t),
I˙H(t) = λH(t)S(t)− (ρ1 + φ+ ψλT (t) + µ)IH(t) + α1A(t) + λH(t)R(t) + ω1CH(t),
A˙(t) = ρ1IH(t) + ω2RH(t)− α1A(t)− (µ+ dA)A(t),
C˙H(t) = φIH(t) + p ρ2ITH(t) + r τ3LTH(t)− (ω1 + µ)CH(t),
L˙TH(t) = β
′
2λT (t)RH(t)− (k2 + τ3 + µ)LTH(t),
I˙TH(t) = δλH(t)IT (t) + ψλT (t)IH(t) + α2AT (t) + k2LTH(t)− (ρ2 + µ+ dT ) ITH(t),
R˙H(t) = qρ2ITH(t) + (1− r) τ3LTH(t)−
(
β
′
2λT (t) + ω2 + µ
)
RH(t),
A˙T (t) = (1− (p+ q))ρ2ITH(t)− (α2 + µ+ dTA)AT (t),
(3)
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Figure 1. Model for TB-HIV/AIDS transmission.
that describes the transmission dynamics of TB and HIV/AIDS disease. The model
flow is illustrated in Figure 1.
2.1. Positivity and boundedness of solutions. Since the system of equations
(3) represents human populations, all parameters in the model are non-negative and
it can be shown that, given non-negative initial values, the solutions of the system
are non-negative. Consider the biologically feasible region
Ω = {(S,LT , IT , R, IH , A,CH , LTH , ITH , RH , AT ) ∈ R11+ : N ≤ Λ/µ}.
In what follows we prove the positive invariance of Ω (i.e., all solutions in Ω remain
in Ω for all time). The rate of change of the total population, obtained by adding
all the equations in model (3), is given by
dN
dt
= Λ− µN(t)− dT IT (t)− dAA(t)− dT ITH(t)− dTAAT (t).
Using a standard comparison theorem [25] we can show that
N(t) ≤ N(0)e−µt + Λ
µ
(
1− e−µt) .
In particular, N(t) ≤ Λµ if N(0) ≤ Λµ . Thus, the region Ω is positively invariant.
Hence, it is sufficient to consider the dynamics of the flow generated by (3) in Ω.
In this region, the model is epidemiologically and mathematically well posed [20].
Thus, every solution of the model (3) with initial conditions in Ω remains in Ω for
all t > 0. This result is summarized below.
Lemma 2.1. The region Ω is positively invariant for the model (3) with non-
negative initial conditions in R11+ .
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3. Analysis of the sub-models. In this section we analyze the models for HIV
only (HIV-only model) and TB only (TB-only model).
3.1. HIV-only model. The model that considers only HIV (obtained by setting
LT = IT = R = LTH = ITH = RH = AT ) is given by
S˙(t) = Λ− λH(t)S(t)− µS(t),
I˙H(t) = λH(t)S(t)− (ρ1 + φ+ µ)IH(t) + α1A(t) + ω1CH ,
A˙(t) = ρ1IH(t)− (α1 + µ+ dA)A(t),
C˙H(t) = φIH(t)− (ω1 + µ)CH(t),
(4)
where
λH(t) =
β2
N(t)
[IH(t) + ηCCH(t) + ηAA(t)]
with
N(t) = S(t) + IH(t) +A(t) + CH(t).
Analogously to Lemma 2.1, we can prove that the region
Ω1 = {(S, IH , A,CH) ∈ R4+ : N ≤ Λ/µ} (5)
is positively invariant and attracting. Thus, the dynamics of the HIV-only model
will be considered in Ω1.
3.1.1. Persistence. In this section, we look for the conditions under which the host
population and disease will persist. Rewriting the submodel system (4) as
S˙(t) = Λ− β2(N)(IH+ηC CH+ηAA)N S(t)− µS(t),
I˙H(t) =
β2(N)(IH+ηC CH+ηAA)
N S(t)− (ρ1 + φ+ µ)IH(t) + α1A(t) + ω1CH ,
C˙H(t) = φIH(t)− (ω1 + µ)CH(t),
A˙(t) = ρ1IH(t)− (α1 + µ+ dA)A(t),
(6)
in what follows we assume that β2(N) is continuous for N ≥ 0 and continuously
differentiable for N > 0; β2(N) is monotone nondecreasing in N ; and β2(N) > 0 if
N > 0.
Remark 2. In this work β2 denotes the effective contact rate for HIV transmission.
It is a constant for a concrete situation, but one can look to it as variable in the
sense that, depending on the situation/region, one can have different values for this
parameter. This is so because β2 is related with the level of contagion/propagation
of the disease. In Section 5 we consider fixed values for β1 and β2, which represent
specific cases of the infection level. By varying β1 and β2 we vary the basic repro-
duction numbers (see expressions (12) and (20) for R1 and R2, respectively). Here
we consider β2 as a function of N to discuss persistence.
It is convenient to reformulate the model in terms of the fractions of the S, IH ,
A and CH parts of the population,
x =
S
N
, y =
IH
N
, z =
CH
N
, w =
A
N
, (7)
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and express (6) in these terms to obtain the system
N˙ = Λ− (µ+ dAw)N,
x˙ = ΛN (1− x)− β2(N)(y + ηCz + ηAw)x+ x(µ− y + dAw),
y˙ = β2(N)(y + ηCZ + ηAw)x+ ydAw − (ρ1 + φ+ µ) y + α1w + ω1z,
z˙ = φy − (ω1 + µ− dAw)z,
w˙ = ρ1y − (α1 + µ+ dA − dAw)w.
(8)
Equations (7) suggest that x + y + z + w = 1. The manifold x + y + z + w = 1,
x, y, z, w ≥ 0, is forward invariant under the solution flow of (8), which has a global
solution satisfying (7). We now show conditions under which the host population
will persist.
Theorem 3.1. Let β2(0) = 0, N(0) > 0. Then the population is uniformly persis-
tent, that is,
lim inf
t→∞ N(t) ≥ ε,
where ε > 0 does not depend on the initial data.
Proof. We have to show that the set
X2 = {N = 0, x ≥ 0, y ≥ 0, z ≥ 0, w ≥ 0, x+ y + z + w = 1}
is uniform strong repeller for
X1 = {N > 0, x ≥ 0, y ≥ 0, z ≥ 0, w ≥ 0, x+ y + z + w = 1} .
Theorem 3.2, Theorem 3.3 and Corollary 1 are taken from [3, 44].
Theorem 3.2. Let X be a locally compact metric space with metric d. Let X be
the disjoint union of two sets X1 and X2 such that X2 is compact. Let Φ be a
continuous semiflow on X1. Then X2 is a uniform strong repeller for X1, whenever
it is a uniform weak repeller for X1.
Theorem 3.3. Let D be a bounded interval in R and g : (t0,∞) × D → R be
bounded and uniformly continuous. Further, let x : (t0,∞)→ D be a solution of
x′ = g(t, x),
which is defined on the whole interval (t0,∞). Then there exist sequences sn, tn →
∞ such that
lim
n→∞ g(sn, x∞) = 0 = limn→∞ g(tn, x
∞).
Corollary 1. Let the assumptions of Theorem 3.3 be satisfied. Then
a) lim inft→∞ g(t, x∞) ≥ 0 ≥ lim supt→∞ g(t, x∞),
b) lim inft→∞ g(t, x∞) ≥ 0 ≥ lim supt→∞ g(t, x∞).
As the assumptions of Theorem 3.2 are satisfied, it suffices to show that X2 is a
uniform weak repeller for X1. Let r = y + z + w. Then,
r′ = β2(N)(yx+ ηCzx+ ηAwx) + dAwr − µr − dAw
≤ β2(N)(1 + ηC + ηA)− Λ
N
r + dA(r − 1),
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using the fact that x, y, z, w, r ≤ 1. This implies that
Λ
N∞
r∞ + (1− r∞)dA ≤ β2(N∞)(1 + ηC + ηA)
⇒ β2(N∞) ≥ Λr
∞
N∞ (1 + ηC + ηA)
+
(1− r∞)dA
1 + ηC + ηA
.
(9)
From the equation of N in (8) we have
lim inf
t→∞
1
N
dN
dt
≥ Λ
N∞
− (µ+ dAw∞) ≥ Λ
N∞
− (µ+ dAr∞) .
Hence N increases exponentially, unless
Λ
N∞
≤ µ+ dAr∞, that is, 1
dA
(
Λ
N∞
− µ
)
≤ r∞. (10)
Combining (9) and (10), we obtain that
β2(N
∞) ≥
(
Λ
dAN∞(1 + ηC + ηA)
− 1
1 + ηC + ηA
)(
Λ
N∞
− µ
)
+
dA
1 + ηC + ηA
,
(11)
as β2(0) = 0 and β2(N) is continuous at 0, N
∞ ≥ ε > 0 with ε not depending on
the initial data. From (11) we see that we can relax β2(0) = 0 and require
β2(0) <
(
Λ
dAN∞(1 + ηC + ηA)
− 1
1 + ηC + ηA
)(
Λ
N∞
− µ
)
+
dA
1 + ηC + ηA
.
This concludes the proof.
The disease is persistent in the population if the fraction of the infected and
AIDS cases is bounded away from zero. If the population dies out and the fraction
of the infected and AIDS remains bounded away from zero, we would still say that
the disease is persistent in the population.
Proposition 3.4. Let β2(∞)(1+ηC+ηA) ≥ ΛN∞ r∞. Then the disease is uniformly
weakly persistent insofar as
r∞ = lim sup
t→∞
r(t) ≥ ε,
with ε > 0 being independent of the initial data, provided that r(0) > 0.
The proof of Proposition 3.4 is outlined in [44].
3.1.2. Local stability of disease-free equilibrium. The model (4) has a disease-free
equilibrium (DFE), obtained by setting the right-hand sides of the equations in the
model to zero, given by
Σ0 = (S
∗, I∗H , A
∗, C∗H) =
(
Λ
µ
, 0, 0, 0
)
.
The linear stability of Σ0 can be established using the next-generation operator
method on the system (4). Following [46], the basic reproduction number is obtained
as the spectral radius of the matrix FV −1 at the DFE, Σ0, with F and V given by,
respectively,
F =

0 0 0 0
λH
β2 S
N
β2 ηA S
N
β2 ηC S
N
0 0 0 0
0 0 0 0

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and
V =

λH + µ
β2 S
N
β2 ηA S
N
β2 ηC S
N
0 C1 −α1 −ω1
0 −ρ1 C2 0
0 −φ 0 C3
 ,
where C1 = ρ1 + φ + µ, C2 = α1 + µ + dA, C3 = ω1 + µ. The basic reproduction
number is given by the dominant eigenvalue of the matrix FV −1, that is,
R1 =
β2 Λ (C3(C2 + ηA ρ1) + ηC φC2)
Nµ [µ (C3(ρ1 + C2) + C2φ+ ρ1dA) + ρ1ω1dA]
. (12)
The basic reproduction number R1 represents the expected average number of new
HIV infections produced by a single HIV-infected individual when in contact with
a completely susceptible population [46].
Remark 3. The next-generation matrix is one of the most well known methods
in epidemiology to compute the basic reproduction number for a compartmental
model of the spread of infectious diseases. To calculate the basic reproduction
number through this method, the whole population is divided into n compartments
in which there are m < n infected compartments. Let xi, i = 1, 2, . . . ,m, be the
numbers of infected individuals in the ith infected compartment at time t. Now,
the epidemic model is x′i = Fi(x)− Vi(x) or, in vector form, x′ = F (x)− V (x). Let
x0 denote here the disease-free equilibrium state. The Jacobian matrices of F (x)
and V (x) are, respectively,
DF (x) =
[
F 0
0 0
]
and DV (x) =
[
V 0
J3 J4
]
,
where F and V are the m×m matrices given by
F =
[
∂Fi(x0)
∂xj
]
, V =
[
∂Vi(x0)
∂xj
]
.
The matrix FV −1 is known as the next-generation matrix and its spectral radius is
the basic reproduction number of the model. The reader interested in all the details
about the computation of the basic reproduction number by the next-generation
matrix is referred to [14, 46] or any good book on dynamical modeling and analysis
of epidemics (e.g., [13]).
Lemma 3.5. The disease free equilibrium Σ0 is locally asymptotically stable if R1 <
1, and unstable if R1 > 1.
Proof. Following Theorem 2 of [46], the disease-free equilibrium, Σ0, is locally
asymptotically stable if all the eigenvalues of the Jacobian matrix of the system
(4), here denoted by M (Σ0), computed at the DFE Σ0, have negative real parts.
The Jacobian matrix of the system (4) at disease free equilibrium Σ0 is given by
M (Σ0) =

−µ −β2 ΛµN −β2 ηA ΛµN −β2 ηC ΛµN
0 β2 ΛµN − C1 β2 ηA ΛµN + α1 β2 ηC ΛµN + ω1
0 ρ1 C2 0
0 φ 0 C3
 . (13)
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One has
trace [M (Σ0)] = −µ+ β2 Λ
µN
− (C1 + C2 + C3) < 0
and
det [M (Σ0)] = −β2 Λ
N
[C3(C2 + ρ1ηA) + φηCC2]
+ µ [µ (C3(ρ1 + C2) + C2φ+ ρ1dA) + ρ1ω1dA] > 0
for R1 < 1. We have just proved that the disease free equilibrium Σ0 of model (4)
is locally asymptotically stable if R1 < 1, and unstable if R1 > 1.
3.1.3. Global stability of disease-free equilibrium (DFE). Following [8], let us rewrite
the submodel system (4) as
dX
dt
= F (X,Z),
dZ
dt
= G(X,Z), G(X, 0) = 0,
(14)
where X = S and Z = (IH , A,CH), with X ∈ R+ denoting the total number of un-
infected individuals and Z ∈ R3+ denoting the total number of infected individuals.
The disease-free equilibrium is now denoted by
U0 = (X0, 0), where X0 =
(
Λ
µ
, 0
)
.
The conditions (H1) and (H2) below must be met to guarantee global asymptotically
stability:
(H1) for dXdt = F (X, 0), U0 is globally asymptotically stable;
(H2) G(X,Z) = AZ−Gˆ(X,Z), Gˆ(X,Z) ≥ 0 for (X,Z) ∈ G, whereA = DZG(U0, 0)
is a Metzler matrix (the off diagonal elements of A are nonnegative) and G is
the region where the model makes biological sense.
Theorem 3.6. The fixed point U0 = (X0, 0) is a globally asymptotically stable
equilibrium of (4) provided R1 < 1 and the assumptions (H1) and (H2) are satisfied.
Proof. We have
dX
dt
= F (X,Z) =
[
Λ− λHS − µS
]
,
F (X, 0) =
[
Λ− µS ] ,
dZ
dt
= G(X,Z) =

λH(t)S(t)− C1IH(t) + α1A(t) + ω1CH
ρ1IH(t)− C2A(t)
φIH(t)− C3CH(t)
 ,
and G(X, 0) = 0. Therefore,
dX
dt
= F (X, 0) =
[
Λ− µS
−µRT
]
,
A = DZG(X0, 0) =

β2 Λ
Nµ − C1 β2 ηA ΛNµ + α1 β2 ηC ΛNµ + ω1
ρ1 −C2 0
φ 0 −C3

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and
Gˆ(X,Z) =

Gˆ1(X,Z)
Gˆ2(X,Z)
Gˆ3(X,Z)
 =
 β2(1− 1N )(IH + ηAA+ ηCCH)0
0
. (15)
It follows that Gˆ1(X,Z) ≥ 0, Gˆ2(X,Z) = Gˆ3(X,Z) = 0. Thus, Gˆ(X,Z) ≥ 0.
Conditions (H1) and (H2) are satisfied, and we conclude that U0 is globally asymp-
totically stable for R1 < 1.
3.1.4. Existence of an endemic equilibrium. To find conditions for the existence of
an equilibrium for which HIV is endemic in the population (i.e., at least one of I∗H ,
A∗ or C∗H is non-zero), denoted by ΣH = (S
∗, I∗H , A
∗, C∗H), the equations in (4) are
solved in terms of the force of infection at steady-state (λ∗H), given by
λ∗H =
β2 (I
∗
H + ηAA
∗ + ηC C∗H)
N∗
. (16)
Setting the right hand sides of the model to zero (and noting that λH = λ
∗
H at
equilibrium) gives
S∗ =
Λ
λ∗H + µ
, I∗H = −
λ∗HΛC2C3
D
, A∗ = −ρ1λ
∗
HΛC3
D
, C∗H = −
φλ∗HΛC2
D
,
(17)
with D = −(λ∗H + µ)(µ (C3(ρ1 + C2) + C2φ+ ρ1dA) + ρ1ω1dA). Using (17) in the
expression for λ∗H in (16) shows that the nonzero (endemic) equilibria of the model
satisfy
λ∗H =
Λβ2 (C2C3 + ηAρ1C3 + ηCφC2)
N [µ (C3(ρ1 + C2) + C2φ+ ρ1dA) + ρ1ω1dA]
− µ,
that is,
λ∗H = −µ(1−R1).
The force of infection at the steady-state λ∗H is positive, only if R1 > 1. We have
just proved the following result.
Lemma 3.7. The submodel system (4) has a unique endemic equilibrium whenever
R1 > 1.
3.1.5. Local stability of the endemic equilibrium. In what follows we prove the local
asymptotic stability of the endemic equilibrium ΣH , using the center manifold the-
ory [6], as described in [9, Theorem 4.1], with ΣH = (S
∗, I∗H , A
∗, C∗H) and each of its
components given as in (17). To apply this method, the following simplification and
change of variables are first made. Let S = x1, IH = x2, A = x3 and CH = x4, so
that N = x1 +x2 +x3 +x4. Further, by using vector notation X = (x1, x2, x3, x4)
T ,
the submodel (4) can be written in the form dXdt = (f1, f2, f3, f4)
T , as follows:
dx1
dt
= f1 = Λ− β2 (x2 + ηAx3 + ηCx4)
x1 + x2 + x3 + x4
x1 − µx1,
dx2
dt
= f2 =
β2 (x2 + ηAx3 + ηCx4)
x1 + x2 + x3 + x4
x1 − C1x2 + α1x3 + ω1x4,
dx3
dt
= f3 = ρ1x2 − C2x3,
dx4
dt
= f4 = φx2 − C3x4.
(18)
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The basic reproduction number of the submodel (4) is given by (12). Choose as
bifurcation parameter β∗, by solving for β2 from R1 = 1:
β∗ =
µ (C3(ρ1 + C2) + C2φ+ ρ1dA) + ρ1ω1dA
C3(C2 + ηA ρ1) + ηC φC2
.
The submodel (4) has a disease free equilibrium given by
ΣH = (x10, x20, x30, x40) =
(
Λ
µ
, 0, 0, 0
)
.
The Jacobian of the system (18), evaluated at Σ0, M (Σ0), and with β2 = β
∗, is
given by (13). Note that the above linearized system, of the transformed system
(18) with β2 = β
∗, has a zero eigenvalue which is simple. Hence, the center manifold
theory [6] can be used to analyze the dynamics of (18) near β2 = β
∗. In particular,
Theorem 4.1 in [9] is used to show the locally asymptotically stability of the endemic
equilibrium point of (18), for β2 near β
∗.
The Jacobian M(Σ0) at β2 = β
∗ has a right eigenvector (associated with the
zero eigenvalue) given by w = [w1, w2, w3, w4]
T , where
w1 = −w3 µ(C3(ρ1 + C2) + C2φ+ ρ1dA) + ρ1ω1dA
C3µρ1
,
w2 =
w3 C2
ρ1
,
w3 = w3 > 0,
w4 =
C2φw3
C3ρ1
.
Further, M(Σ0) for β2 = β
∗ has a left eigenvector v = [v1, v2, v3, v4] (associated
with the zero eigenvalue), where
v1 = 0,
v2 = v3
C2C3 + ηAρ1C3 + ηCφC2
µ(ηAC1 + ηAω1 + α1) + ω1ηAρ1 + (ηCφ+ ω1)α1
,
v3 = v3 > 0,
v4 = v3
ηCC2 + µ(ω1 + ηCρ1 + ηCφ) + ρ1(ω1ηA + ηCdA) + (ω1 + ηCφ)(α1 + dA)
µ (ηAC1 + ηAω1 + α1) + ω1(ηAρ1 + α1) + ηCφα1
.
To apply Theorem 4.1 in [9] it is convenient to let fk represent the right-hand side of
the kth equation of the system (18) and let xk be the state variable whose derivative
is given by the kth equation for k = 1, . . . , 4. The local stability near the bifurcation
point β2 = β
∗ is then determined by the signs of two associated constants, denoted
by a and b, defined (respectively) by
a =
4∑
k,i,j=1
vkwiwj
∂2fk
∂xi∂xj
(0, 0) and b =
4∑
k,i=1
vkwi
∂2fk
∂xi∂φ
(0, 0)
with φ = β2 − β∗. Note that, in fk(0, 0), the first zero corresponds to the DFE,
Σ0, for the subsystem (4). In other words, fk(0, φ) = 0, for k = 1, . . . , 4, if and
only if the right-hand sides of the equations of (4) is zero at Σ0. Moreover, from
φ = β2−β∗ we have φ = 0 when β2 = β∗, which is the second component in fk(0, 0).
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For the system (18), the associated non-zero partial derivatives at the disease
free equilibrium Σ0 are given by
∂2f1
∂x22
=
2β∗µ
Λ
,
∂2f1
∂x2∂x3
=
β∗µ(1 + ηA)
Λ
,
∂2f1
∂x2∂x4
=
β∗µ(1 + ηC)
Λ
,
∂2f1
∂x23
=
2β∗µηA
Λ
,
∂2f1
∂x3∂x4
=
β∗µ(ηA + ηC)
Λ
,
∂2f1
∂x4∂x2
=
β∗µ(1 + ηC)
Λ
,
∂2f1
∂x24
=
2β∗µηC
Λ
,
∂2f2
∂x22
=
2β∗µ
Λ
,
∂2f2
∂x2∂x3
= −β
∗µ(1 + ηA)
Λ
,
∂2f2
∂x2∂x4
= −β
∗µ(1 + ηC)
Λ
,
∂2f2
∂x23
= −2β
∗ηAµ
Λ
,
∂2f2
∂x3∂x4
= −β
∗µ(ηA + ηC)
Λ
,
∂2f2
∂x24
= −2β
∗ηCµ
Λ
,
∂2f2
∂x4∂x2
= −β
∗µ(1 + ηC)
Λ
.
It follows from the above expressions that
a =
w23C2φβ2µ (ηA + ηC)
ρ1 (ω1 + µ) Λ
− 2D1C
2
2 (C3 + φ(1 + ηC))
D2ρ21C3
− 2D1
(
C2C3ρ1 (C3(1 + ηA) + φ) + C
2
3ηAρ
2
1 + C
2
2φ
2ηC
)
D2ρ21C
2
3
,
with
D1 = v3w
2
3β2µ (C3C2 + C3ηAρ1 + ηCφC2) ,
D2 = Λ (ηAρ1C3 + C3α1 + ηAµC3 + µφ+ ηCφα1) .
For the sign of b, it can be shown that the associated non-vanishing partial deriva-
tives are
∂2f1
∂x2∂β∗
= −1, ∂
2f1
∂x3∂β∗
= −ηA, ∂
2f1
∂x4∂β∗
= −ηC ,
∂2f2
∂x2∂β∗
= −1, ∂
2f2
∂x3∂β∗
= −ηA, ∂
2f2
∂x4∂β∗
= ηC .
It also follows from the above expressions that
b =
((ηA + ηC)ρ1 + C2) (C3C2 + C3ηAρ1 + ηCφC2) v3w3
((ηAρ1 + α1 + ηAµ)C3 + ηAµφ+ ηCφα1) ρ1
.
From the previous computations, we have a < 0 and b > 0. Thus, using Theorem 4.1
of [9], the following result is established.
Theorem 3.8. The endemic equilibrium ΣH is locally asymptotically stable for the
basic reproduction number R1 (12) near 1.
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3.2. TB-only model. The sub-model of (3) with no HIV/AIDS disease, that is,
IH = A = CH = LTH = ITH = RH = AT = 0, is given by
S˙(t) = Λ− λT (t)S(t)− µS(t),
L˙T (t) = λT (t)S(t) + β
′
1λT (t)R(t)− (k1 + τ1 + µ)LT (t),
I˙T (t) = k1LT (t)− (τ2 + dT + µ)IT (t),
R˙(t) = τ1LT (t) + τ2IT (t)− (β′1λT (t) + µ)R(t),
(19)
where
λT (t) =
β1IT (t)
N(t)
and
N(t) = S(t) + LT (t) + IT (t) +R(t).
The sub-model (19) was proposed and analyzed in [7]. This model incorporates the
basic properties of TB transmission and dynamics. The basic reproduction number
R2 of (19) is given by
R2 =
Λ
µN
(
β1
µ+ dT + τ2
)(
k1
µ+ k1 + τ1
)
. (20)
The existence, uniqueness and local asymptotic stability of the disease-free and
endemic equilibria are proven in [7, Theorem 1].
4. Analysis of the full model. We now consider the full model (3), with the
DFE given by
Ξ0 = (S
, LT , I

T , R
, IH , A
, CH , L

TH , I

TH , R

H , A

T )
=
(
Λ
µ
, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0
)
.
The associated matrices F and V (see Section 3.1.2) are given, respectively, by
F =
[
F1 F2
]
with
F1 =

0 0 0 0 0 0
λT 0
β1(S+Rβ
′
1)
N β
′
1λT 0 0
0 0 0 0 0 0
0 0 0 0 0 0
λH 0 0 λH
β2(S+R)
N
β2ηA(S+R)
N
0 0 0 0 0 0
0 0 0 0 0 0
0 0
β′2 β1RH
N 0 0 0
0 0 δλH +
ψ β1IH
N 0
δβ2IT
N + ψλT
δβ2ηAIT
N
0 0 0 0 0 0
0 0 0 0 0 0

,
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F2 =

0 0 0 0 0
0 0
β1(S+Rβ
′
1)
N 0
β1(S+Rβ
′
1)
N
0 0 0 0 0
0 0 0 0 0
β2ηC(S+R)
N
β2(S+R)
N
β2(S+R)
N
β2(S+R)
N
β2ηA(S+R)
N
0 0 0 0 0
0 0 0 0 0
0
β′2 β1RH
N β
′
2λT
β′2 β1RH
N 0
δβ2IT
N
δβ2IT
N +
ψβ1IH
N
δβ2IT
N
δβ2ηAIT
N +
ψβ1IH
N 0
0 0 0 0 0
0 0 0 0 0

,
and V = [V1 V2] with
V1 =

λT + λH + µ 0
β1S
N 0
β2S
N
β2SηA
N
0 C4 0 0 0 0
0 −k1 δλH + C5 0 δβ2ITN δβ2ηAITN
0 −τ1 β
′
1β1R−τ2N
N β
′
1λT + λH + µ
β2R
N
β2ηAR
N
0 0 ψβ1IHN 0 ψλT + C1 −α1
0 0 0 0 −ρ1 C2
0 0 0 0 −φ 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0
β′2β1RH
N 0 0 0
0 0 0 0 0 0

and
V2 =

β2ηCS
N
β2S
N
(β1+β2)S
N
β2S
N
(β1+β2ηA)S
N
0 0 0 0 0
δβ2ηCIT
N
δβ2IT
N
δβ2IT
N
δβ2IT
N
δβ2ηAIT
N
β2ηCR
N
β2R
N
(β′1β1+β2)R
N
β2R
N
(β′1β1+β2ηA)R
N
−ω1 0 ψβ1IHN 0 ψβ1IHN
0 β2RN 0 −ω2 0
ω1 + µ −r τ3 −p ρ2 0 0
0 C6 0 0 0
0 −k2 C7 0 −α2
0 (−1 + r) τ3 −q ρ2 + β
′
2β1RH
N β
′
2λT + ω2 + µ
β′2β1RH
N
0 0 (−1 + p+ q) ρ2 0 C8

,
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where C4 = k1 + τ1 + µ, C5 = τ2 + µ+ dT , C6 = k2 + τ3 + µ, C7 = ρ2 + µ+ dT and
C8 = α2 + dTA + µ. The dominant eigenvalues of the matrix FV
−1 are
R1 =
β2 Λ (C3(C2 + ηA ρ1) + ηC φC2)
Nµ [µ (C3(ρ1 + C2) + C2φ+ ρ1dA) + ρ1ω1dA]
, R2 =
Λβ1k1
µNC5C4
.
Thus, the basic reproduction number R0 of the model (21) is given by
R0 = max{R1, R2}.
Using the same procedure as in Section 3.1.2, the following result holds.
Lemma 4.1. The DFE of the full HIV-TB model (3), given by Ξ0, is locally asymp-
totically stable if R0 < 1, and unstable if R0 > 1.
Remark 4. There are different ways to compute the basic reproduction number
R0. Here we are computing it using one of the most well-known methods: R0
is the dominant eigenvalue of the associated next-generation matrix FV −1 (see
Remark 3). A justification for the value of the basic reproduction number R0 to be
max{R1, R2} is given in Section 4.4 of [46].
5. Optimal control problem. In this section we present an optimal control prob-
lem, describing our goal and the restrictions of the epidemic. In the model without
controls discussed so far, we have p representing the fraction of ITH individuals that
take HIV and TB treatment and q representing the fraction of ITH individuals that
take TB treatment only. Roughly speaking, the problem of optimal control consists
to determine the optimal combination for the values of p and q. For this reason, we
take p as the control u1 and q as the control u2. Precisely, we add to the model (3)
the two control functions u1(·) and u2(·) in the following way:
S˙(t) = Λ− λT (t)S(t)− λH(t)S(t)− µS(t),
L˙T (t) = λT (t)S(t) + β
′
1λT (t)R(t)− (k1 + τ1 + µ)LT (t),
I˙T (t) = k1LT (t)− (τ2 + dT + µ+ δλH(t)) IT (t),
R˙(t) = τ1LT (t) + τ2IT (t)− (β′1λT (t) + λH(t) + µ)R(t),
I˙H(t) = λH(t)S(t)− (ρ1 + φ+ ψλT (t) + µ)IH(t) + α1A(t) + λH(t)R(t) + ω1CH(t),
A˙(t) = ρ1IH(t) + ω2RH(t)− α1A(t)− (µ+ dA)A(t),
C˙H(t) = φIH(t) + u1(t) ρ2ITH(t) + r τ3LTH(t)− (ω1 + µ)CH(t),
L˙TH(t) = β
′
2λT (t)RH(t)− (k2 + τ3 + µ)LTH(t),
I˙TH(t) = δλH(t)IT (t) + ψλT (t)IH(t) + α2AT (t) + k2LTH(t)− (ρ2 + µ+ dT ) ITH(t),
R˙H(t) = u2(t)ρ2ITH(t) + (1− r) τ3LTH(t)−
(
β
′
2λT (t) + ω2 + µ
)
RH(t),
A˙T (t) = (1− (u1(t) + u2(t))) ρ2ITH(t)− (α2 + µ+ dTA)AT (t).
(21)
As already mentioned, the controls u1 and u2 represent the fraction of ITH in-
dividuals that are treated for TB and HIV (simultaneously) and treated for TB
only, respectively. If we consider fixed values for u1 and u2 in (21), then we get
the model (3) with u1 = p and u2 = q. The aim is to find the optimal values
u∗1 and u
∗
2 of the controls u1 and u2, such that the associated state trajectories
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S∗, L∗T , I
∗
T , R
∗, I∗H , A
∗, C∗H , L
∗
TH , I
∗
TH , R
∗
H , A
∗
T , solution of the system (21) in the
time interval [0, T ] with initial conditions S∗(0), L∗T (0), I
∗
T (0), R
∗(0), I∗H(0), A
∗(0),
C∗H(0), L
∗
TH(0), I
∗
TH(0), R
∗
H(0), A
∗
T (0), minimize the objective functional. Here the
objective functional considers the number of HIV-infected individuals with AIDS
symptoms co-infected with TB AT , and the implementation cost of the strategies
associated to the controls ui, i = 1, 2. The controls are bounded between 0 and
0.95. We assume that p and q cannot take values greater than 0.95 because we
assume that there are some budgetary constraints or some resistance from patients
in making the treatments (treatment for HIV and TB together or just the treatment
for TB). In other words, we assume that one cannot treat all the people for both
diseases or even just for tuberculosis. This is more than reasonable from biological
side. Moreover, the sum of p + q is also taken as bounded by 0.95. This is related
with the formulation of the model. Indeed, note that 1 − (p + q) is the fraction of
ITH individuals who are not treated for TB and HIV simultaneously and are also
not treated for TB alone. For this reason, what we assume is that this fraction
of individuals takes at least the value of 5%. This is in agreement with available
medical data. Precisely, we consider the state system (21) of ordinary differential
equations in R11 with the set of admissible control functions given by
Θ =
{
(u1(·), u2(·)) ∈ (L∞(0, T ))2 | 0 ≤ u1(t), u2(t) ≤ 0.95
and 0 ≤ u1(t) + u2(t) ≤ 0.95, ∀ t ∈ [0, T ]
}
. (22)
The objective functional is given by
J(u1(·), u2(·)) =
∫ T
0
[
AT (t) +
W1
2
u21(t) +
W2
2
u22(t)
]
dt, (23)
where the constantsW1 andW2 are a measure of the relative cost of the interventions
associated to the controls u1 and u2, respectively.
Remark 5. Epidemiologically, our cost functional tells us that we want to mini-
mize the number of HIV-infected individuals with AIDS symptoms co-infected with
active TB. For that, one applies control measures that are associated with some
implementation costs that we also intend to minimize. Other cost functionals may
be used as well. Here, by considering the cost with controls in a quadratic form,
we are being consistent with previous works in the literature (see, e.g., [35, 42]).
Moreover, a quadratic structure in the control has mathematical advantages: if the
control set is a compact and convex polyhedron (as it is the case here), it imply
that the Hamiltonian attains its minimum over the control set at a unique point.
For future work we plan to compare the results now obtained, for a cost with a
quadratic form in the controls, with those of a linear cost in the controls.
In order to simplify the formulation of the optimal control problem, let fi rep-
resent the right-hand side of the ith equation of system (21), xi be the state vari-
able whose derivative is given by the ith component of F , F = (f1, . . . , f11), and
X = (x1, . . . , x11), i = 1, . . . , 11. We consider the optimal control problem of deter-
mining X∗(·) associated to an admissible control pair (u∗1(·), u∗2(·)) ∈ Θ on the time
interval [0, T ], satisfying (21), the initial conditions X(0) and minimizing the cost
function (23), that is,
J(u∗1(·), u∗2(·)) = min
Θ
J(u1(·), u2(·)). (24)
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The existence of optimal controls (u∗1(·), u∗2(·)) comes from the convexity of the cost
functional (23) with respect to the controls and the regularity of the system (21) (see,
e.g., [10, 16] for existence results of optimal solutions). According to the Pontryagin
maximum principle [31], if (u∗1(·), u∗2(·)) ∈ Θ is optimal for the problem (21), (24)
with the initial conditions X(0) and fixed final time T , then there exists a nontrivial
absolutely continuous mapping λ : [0, T ] → R11, λ(t) = (λ1(t), . . . , λ11(t)), called
adjoint vector, such that
x˙i =
∂H
∂λi
(X,λ, u1, u2), λ˙i = −∂H
∂xi
(X,λ, u1, u2), i = 1, . . . , 11, (25)
where the function H = H(X,λ, u1, u2) defined by
H = AT +
W1
2
u21 +
W2
2
u22 + 〈λ, F (X,u1, u2)〉
is called the Hamiltonian, and the minimality condition
H(X∗(t), λ∗(t), u∗1(t), u
∗
2(t)) = min
0≤u1,u2≤0.95
u1+u2≤0.95
H(X∗(t), λ∗(t), u1, u2) (26)
holds almost everywhere on [0, T ]. Moreover, the transversality conditions
λi(T ) = 0, i = 1, . . . , 11,
are also satisfied.
6. Numerical results and discussion. In this section we present results of the
numerical implementation of extremal control strategies for the TB-HIV model (21).
First we solve numerically the optimal control problem (21), (24) with initial condi-
S(0) LT (0) IT (0) R(0) IH(0) A(0)
66N(0)
120
37N(0)
120
5N(0)
120
2N(0)
120
2N(0)
120
N(0)
120
CH(0) LTH(0) ITH(0) RH(0) AT (0)
N(0)
120
2N(0)
120
2N(0)
120
N(0)
120
N(0)
120
Table 1. Initial conditions of the TB-HIV/AIDS model, where
N(0) = 30000.
tions given in Table 1, and fixed final time T = 50 years. The initial conditions were
estimated as follows. We assume that more than half of population (55%) belongs
to the subgroup of susceptible and that a big percentage (' 31%) is infected with
TB but is in the latent stage. This is justified from the fact that “about one-third of
the world’s population has latent TB”, as one can find in the website of the World
Health Organization (WHO) [49]. The value for the fraction of people infected with
HIV is assumed ' 1.7%, based on HIV & AIDS Information from AVERT.org [1]:
“There is either a generalised or concentrated epidemic. In a generalised epidemic,
HIV prevalence is 1% or more in the general population. In a concentrated or low
level epidemics, HIV prevalence is below 1% in the general population but exceeds
5% in specific at-risk populations like injecting drug users or sex workers, or HIV
prevalence is not recorded at a significant level in any group.” The remaining values
are estimated by assuming that we are in a “controlled” situation, without large
percentages in the groups of highest risk such as A, AT and CH . Our aim is to
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find the optimal combination of the fraction of individuals ITH that take correctly
HIV and TB treatment (u∗1) or take only TB treatment (u
∗
2), in order to minimize
the number of individuals with AIDS and TB diseases AT . Different approaches
were used to obtain and confirm the numerical results. One approach consisted in
using IPOPT (short for “Interior Point OPTimizer”, a software library for large
scale nonlinear optimization of continuous systems) [47] and the algebraic modeling
language AMPL (acronym for “A Mathematical Programming Language”) [17]. A
second approach was to use the PROPT Matlab Optimal Control Software [32].
For more details we refer the reader to [41, 42], where the same optimization ap-
proaches are used. In Figure 2 we compare the extremal dynamics C∗H , I
∗
TH and A
∗
T
associated to the extremal controls u∗1 and u
∗
2 with the dynamics of the model (21)
with u1(t) = p and u2(t) = q, which coincide with model (3). In this simulations
we consider β1 = 0.6, β2 = 0.1 and the rest of the parameters take the values of
Table 2, which corresponds to R0 = 4.91159 (R1 = 4.91159, R2 = 1.07437). We
assume that the weight constants take the same value W1 = W2 = 50. Observe that
the number of individuals with AIDS and TB diseases AT decreases significantly
when the control measures u∗1, u
∗
2 are implemented, see Figure 2 (c). On the other
hand, the number of individuals that stays in the class CH increases in opposition
to the number of individuals that have both infections HIV and TB, see Figure 2 (a)
and (b). During approximately 40 years the optimal combination of the fractions
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Figure 2. Dynamics CH , ITH and AT for cost functional (23),
β1 = 0.6, β2 = 0.1, W1 = W2 = 50 and parameter values from
Table 2.
of individuals ITH that take HIV and TB treatments simultaneously and only TB
treatment is around 0.5 and 0.46, respectively, see Figure 3 (a) and (b). In Figure 3
(c) we observe that the extremal controls satisfy the restriction (22). At the end
of 50 years, the number of TB and AIDS induced deaths reduces 5% when the con-
trols u∗1, u
∗
2 are applied, see Figure 4. Since the HIV treatments have higher costs
than TB treatment, we can consider that the weight constant W1 associated to the
control u1 takes greater values than W2. In this case, the fraction of individuals
that take TB and HIV treatment u∗1 decreases and the fraction of individuals that
take only TB treatment increases, compared to the previous case W1 = W2 = 50,
but the associated extremal dynamics C∗H , I
∗
H and A
∗
T behave similarly to the ones
in the case W1 = W2 = 50, see Figure 5. The extremal controls in Figure 5 (a) and
(b) are not intuitive, since the fraction of individuals that take both HIV and TB
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Figure 3. Extremal controls u∗1 and u
∗
2 for cost functional (23),
β1 = 0.6, β2 = 0.1, W1 = W2 = 50 and parameter values from
Table 2.
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Figure 5. Extremal controls u∗1 and u
∗
2 for cost functional (23),
β1 = 0.6, β2 = 0.1, W1 = 500, W2 = 50 and parameter values from
Table 2.
treatments is very low. If we assume that our aim is to minimize the cost functional
J1(u1(·), u2(·)) =
∫ T
0
[
A(t) +AT (t) +
W1
2
u21(t) +
W2
2
u22(t)
]
dt, (27)
with T = 10 years and no disease induced deaths (dT = dTA = dA = 0), that is, we
wish to minimize the number of individuals that have only AIDS A and have both
AIDS and TB diseases AT , the extremal controls behave in a more intuitive way.
Since we assume that there is no disease induced deaths we consider that is more
adequate to consider T = 10 instead of T = 50 years. Moreover, is this case, the
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total population is constant. We observe that the fraction of individuals that take
both HIV and TB treatment u∗1 takes the maximum value for more than 7 years,
and during this time the extremal control u∗2 vanishes, see Figure 6. In this case, we
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Figure 6. Extremal controls u∗1 and u
∗
2 for cost functional J1,
with β1 = 0.6, β2 = 0.1, W1 = W2 = 50 and parameter values from
Table 2.
compare the behavior of the dynamics A, AT , ITH and CH for the following cost
functionals J1, J2 and J3, with W1 = W2 = 50, where
J2(u1(·)) =
∫ T
0
[
A(t) +AT (t) +
W1
2
u21(t)
]
dt, (28)
J3(u2(·)) =
∫ T
0
[
A(t) +AT (t) +
W2
2
u22(t)
]
dt, (29)
that is, when both controls u1 and u2 are applied simultaneously, or are applied
separately. The number of individuals with only AIDS, A, is lower for cost functional
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Figure 7. Extremal controls when u1 and u2 are applied separately.
J1 and with extremal controls given by u
∗
1 and u
∗
2 in Figure 6 (a) and (b), see
Figure 8 (a). However, this is not the best strategy for the reduction of the number
of individuals with both AIDS and TB diseases, AT . In this case, the best strategy
is to apply only control u1 where u1 takes the values given in Figure 7, see Figure 8
(b). The best strategy for the reduction of the total number of individuals with
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only AIDS and with both AIDS and TB, A + AT , during the first six years is the
one associated to the cost functional J2, that is, apply only control u
∗
1 (see Figure 7
(a)) and after six years the best strategy is to apply simultaneously both controls
u∗1 and u
∗
2 given by Figure 6. In Figure 9 we observe that the implementation of
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Figure 8. Dynamics A, AT and A + AT for cost functionals J1,
J2, J3 and u1 = p = 0.1, u2 = q = 0.3, with β1 = 0.6, β2 = 0.1,
W1 = W2 = 50 and parameter values from Table 2.
controls u1 and u2 simultaneously or separately, contribute to the reduction of the
number of individuals infected with HIV and TB, ITH , and increase the number of
individuals that remain in the class CH , that is, the HIV infection does not evolve
to AIDS disease. In this case, the strategy of treating only TB for the individuals in
the class ITH does not allow equal or better results on the reduction of individuals
in the class ITH , which happens in the situation described in Figure 5 for the case
W1 = 500 and W2 = 50.
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Figure 9. Dynamics ITH and CH for cost functionals J1, J2, J3
and u1 = p = 0.1, u2 = q = 0.3, with β1 = 0.6, β2 = 0.1, W1 =
W2 = 50 and parameter values from Table 2.
7. Final comments and future work. Our numerical results only give extremals
and no claims about optimality are made. As future work, it would be interesting
to verify optimality by using second order optimality conditions and addressing
A TB-HIV/AIDS COINFECTION MODEL 23
Symbol Description Value References
N Total population variable
N(0) Initial population 30000
Λ Recruitment rate 430
µ Natural death rate 1/70
β1 TB transmission rate variable
β2 HIV transmission rate variable
ηC Modification parameter 0.9
ηA Modification parameter 1.05
k1 Rate at which individuals leave LT class by
becoming infectious
1/2 [7, 21]
τ1 TB treatment rate for LT individuals 2 [7, 21]
τ2 TB treatment rate for IT individuals 1 [7, 21]
β′1 Modification parameter 0.9
dT TB induced death rate 1/10 [7]
δ Modification parameter 1.03
ψ Modification parameter 1.07
φ HIV treatment rate for IH individuals 1
ρ1 Rate at which individuals leave IH class to A 0.1
α1 AIDS treatment rate 0.33 [3]
ω1 Rate at which individuals leave CH class 0.09
dA AIDS induced death rate 0.3
ρ2 Rate at which individuals leave ITH class 1
p Fraction of ITH individuals that take HIV and
TB treatment
0.1
q Fraction of ITH individuals that take only TB
treatment
0.3
τ3 Rate at which individuals leave LTH class 2
k2 Rate at which individuals leave LTH class by
becoming TB infectious
1.3 k1
r Fraction of LTH individuals that take HIV and
TB treatment
0.3
β′2 Modification parameter 1.1
ω2 Rate at which individuals leave RH class 0.15
α2 HIV treatment rate for AT individuals 0.33
dTA AIDS-TB induced death rate 0.33
Table 2. Parameters of the TB-HIV/AIDS model.
properly the issue of conjugate points. For that, one needs to extend the theory
underlying the computation of conjugate points and verification of optimality as
developed in [38, Section 5.3] and [39].
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